.As cannabis use has become more common in many parts of the world for both medical and recreational purposes, healthcare professionals have continued studying not only its potential therapeutic effects but also its possible risks. While many people associate cannabis with relief from nausea in certain medical settings, doctors have identified a less widely known condition in which long-term or frequent cannabis use may produce the opposite effect.
This condition is known as Cannabis Hyperemesis Syndrome (CHS), a disorder characterized by repeated episodes of severe nausea, persistent vomiting, and abdominal pain in some individuals who use cannabis regularly. Although CHS was first described in medical literature more than two decades ago, awareness among both the public and healthcare providers has increased significantly in recent years.
Emergency physicians in several countries have reported seeing growing numbers of patients whose symptoms initially appear difficult to explain. Many undergo extensive laboratory testing and imaging before clinicians recognize the pattern associated with chronic cannabis use. As awareness improves, physicians hope patients can receive appropriate evaluation and counseling earlier in the course of the illness.
One of the most striking aspects of CHS is that it appears paradoxical. Cannabis has long been used in certain medical situations to help reduce nausea and stimulate appetite, particularly in patients undergoing chemotherapy or experiencing severe illness. However, researchers believe that in susceptible individuals, prolonged or frequent exposure to cannabinoids may eventually disrupt normal regulatory pathways involved in controlling nausea and digestion. Scientists continue investigating the biological mechanisms responsible because the condition does not affect every cannabis user in the same way.
The symptoms associated with CHS can be extremely severe. Individuals often experience repeated episodes of intense nausea accompanied by persistent vomiting that may continue for hours or even days. Many patients also report significant abdominal pain, difficulty keeping down food or fluids, and symptoms related to dehydration. In severe cases, repeated vomiting may require treatment with intravenous fluids and electrolyte replacement in an emergency department or hospital setting.
Healthcare professionals have also observed that many patients experience recurring attacks rather than a single isolated episode. Some individuals recover temporarily only to develop the same symptoms again weeks or months later if cannabis use continues. Because these episodes occur intermittently, patients may not immediately recognize the connection between their symptoms and cannabis use, making diagnosis more challenging. Physicians therefore often ask detailed questions about medical history, medication use, and patterns of cannabis consumption during the evaluation.
The informal term “scromiting” has occasionally been used in media reports and clinical discussions to describe particularly severe episodes in which repeated vomiting is accompanied by cries or screams caused by intense discomfort. Although the expression is not an official medical diagnosis, it reflects the seriousness of symptoms reported by some patients. Doctors emphasize that regardless of terminology, persistent vomiting accompanied by severe abdominal pain requires medical assessment because many other potentially serious conditions can produce similar symptoms.
According to physicians who regularly treat CHS, one unusual feature frequently reported by patients is temporary symptom relief while taking very hot showers or baths. Researchers have not yet fully explained why this occurs, but the observation has become well recognized in emergency medicine. Some clinicians consider this behavior an important clue when evaluating patients with unexplained recurrent vomiting who also report long-term cannabis use. Nevertheless, hot bathing is not considered a treatment for the underlying condition and should not replace appropriate medical care.
At present, there is no medication specifically approved to treat Cannabis Hyperemesis Syndrome itself. Standard anti-nausea medications that are effective for many other causes of vomiting may provide limited benefit for some CHS patients. Physicians sometimes use additional therapies depending on each patient’s symptoms, hydration status, and overall medical condition. Treatment decisions are individualized and based upon clinical judgment, current medical evidence, and the exclusion of other potentially dangerous causes of severe vomiting.
Medical experts generally agree that the most effective long-term strategy currently identified for preventing recurrent CHS episodes is complete cessation of cannabis use. Studies have shown that symptoms frequently improve after cannabis use stops, while continued use often increases the likelihood of recurrence. Because some individuals experience cannabis dependence, healthcare professionals may recommend counseling, addiction treatment resources, or behavioral support to assist patients attempting to discontinue use safely and successfully.
Researchers continue working to understand why only some cannabis users develop CHS while many others do not. Current scientific theories suggest that genetic factors, differences in metabolism, duration of cannabis exposure, frequency of use, potency of products, and individual biological variation may all contribute. However, additional research remains necessary before scientists can fully explain why susceptibility differs so greatly from one individual to another. Continued investigation will help improve diagnosis, prevention, and treatment strategies in the future.
As awareness of Cannabis Hyperemesis Syndrome grows among physicians, researchers, and public health organizations, experts encourage individuals experiencing recurrent unexplained vomiting to discuss their complete medical history—including cannabis use—with healthcare professionals. Early recognition may reduce repeated emergency department visits, unnecessary diagnostic testing, and prolonged discomfort while allowing clinicians to provide appropriate guidance based on each patient’s individual circumstances.
As awareness of Cannabis Hyperemesis Syndrome (CHS) has increased, healthcare providers have become better equipped to recognize its characteristic pattern of symptoms. Nevertheless, diagnosing the condition can still be challenging because persistent vomiting and abdominal pain may also result from numerous other medical disorders. Physicians therefore emphasize that every patient with severe or recurrent vomiting requires a careful medical evaluation to rule out potentially serious conditions before concluding that CHS is the underlying cause.
One reason CHS may initially be overlooked is that many patients are surprised when healthcare providers ask about cannabis use. Because cannabis is sometimes prescribed or used to reduce nausea in certain medical settings, individuals may not expect it to be considered a possible contributor to repeated vomiting. Medical professionals therefore encourage honest communication regarding all medications, supplements, and recreational substances during clinical evaluation, as this information can help guide appropriate diagnosis and treatment.
Researchers continue investigating the biological mechanisms responsible for CHS. One leading theory involves the body’s endocannabinoid system, a complex network of receptors that helps regulate functions such as appetite, digestion, pain perception, mood, and nausea. Scientists believe that prolonged exposure to cannabinoids may alter the normal functioning of this system in susceptible individuals. Although this hypothesis is supported by several studies, researchers acknowledge that additional investigation is needed to fully understand why only certain cannabis users develop the syndrome.
Current evidence also suggests that individual susceptibility varies considerably. Some people who use cannabis frequently never develop CHS, while others experience symptoms after different durations or levels of exposure. Researchers are exploring whether genetics, metabolism, age at first cannabis use, product potency, frequency of use, or other biological factors may influence risk. At present, however, there is no reliable screening test capable of predicting who will eventually develop the condition.
Several published studies have reported increasing numbers of emergency department visits related to CHS over recent years. Researchers attribute this trend to multiple factors, including greater physician awareness, improved recognition of the syndrome, changes in cannabis availability, and increasing use of higher-potency cannabis products in some regions. While these observations help public health officials monitor trends, experts emphasize that additional research is necessary to better understand how patterns of cannabis use influence the incidence of CHS.
Healthcare professionals have also noted that repeated episodes of severe vomiting may lead to complications if left untreated. Significant fluid loss can result in dehydration, while persistent vomiting may contribute to electrolyte imbalances that sometimes require intravenous treatment. In certain cases, repeated vomiting may also irritate the esophagus or make it difficult for patients to maintain adequate nutrition. Prompt medical evaluation therefore remains important whenever symptoms become severe, persistent, or recur frequently.
Treatment during an acute episode primarily focuses on supportive medical care. Physicians often provide intravenous fluids to correct dehydration, monitor electrolyte levels, evaluate for other medical conditions, and administer medications considered appropriate based on the patient’s overall clinical presentation. Because responses to treatment vary among individuals, healthcare teams tailor management according to each patient’s symptoms and medical history. Researchers continue studying which therapeutic approaches provide the greatest benefit for CHS patients.
Medical experts generally agree that complete discontinuation of cannabis remains the most effective long-term strategy currently associated with preventing recurrence of CHS. Many published reports describe substantial improvement after cannabis use stops, although recovery may take time for some individuals. Patients who continue using cannabis after recovering from an episode frequently remain at risk for future recurrences. Because stopping cannabis may be challenging for some people, healthcare providers may recommend behavioral counseling, addiction treatment services, or other forms of professional support when appropriate.
Public health specialists also emphasize the importance of education. As cannabis laws continue evolving in different countries and regions, experts encourage individuals to become informed about both the potential benefits and the possible risks associated with cannabis use. Balanced education allows people to make informed healthcare decisions while recognizing symptoms that warrant medical attention. Increased awareness among patients may also help reduce delays in diagnosis and decrease repeated emergency department visits.
In October 2025, the World Health Organization (WHO) introduced an official diagnostic classification for Cannabis Hyperemesis Syndrome within the International Classification of Diseases (ICD). Public health researchers have noted that standardized diagnostic coding may improve the collection of healthcare data, allowing scientists and policymakers to better monitor the condition, evaluate trends, and support future research. More comprehensive data may ultimately contribute to improved understanding of risk factors, treatment outcomes, and prevention strategies.
Ultimately, Cannabis Hyperemesis Syndrome illustrates the importance of continuing medical research as scientific knowledge evolves. Although many questions remain unanswered, healthcare professionals now recognize CHS as a genuine medical condition that deserves careful evaluation and appropriate treatment. Continued research, increased public awareness, and open communication between patients and healthcare providers will remain essential for improving diagnosis, advancing scientific understanding, and helping individuals receive timely care when symptoms occur.
